Whitehawk Therapeutics Inc (WHWK) 10-Year Financial Performance & Capital Metrics

WHWK • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutWhitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.Show more

Revenue $26M +6.7%
EBITDA -$67M +6.3%
Net Income -$64M +3.2%
EPS (Diluted) -2.36 +3.3%
Gross Margin -108.04% +3.9%
EBITDA Margin -258.88% +12.1%
Operating Margin -259.62% +12.1%
Net Margin -245.13% +9.2%
ROE -80.79% -61.9%
ROIC -148.34% -126.3%
Debt/Equity 0.02 +31.8%
Interest Coverage -438.04 -40.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 82 (top 18%)
✓Strong 5Y sales CAGR of 103.3%
✓Trading at only 1.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y103.26%

3Y185.2%

TTM-9.33%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM84.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM97.52%

ROCE

10Y Avg-86.92%

5Y Avg-86.92%

3Y Avg-59.47%

Latest-84.71%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	749K	14.58M	1.12M	15.22M	24.35M	25.98M
Revenue Growth %	-	18.47%	-0.92%	12.59%	0.6%	0.07%
Cost of Goods Sold+	11.06M	15.01M	19.67M	34M	51.74M	54.05M
COGS % of Revenue	14.77%	1.03%	17.56%	2.23%	2.12%	2.08%
Gross Profit+	-10.32M	-428K	-18.55M	-18.78M	-27.38M	-28.07M
Gross Margin %	-13.77%	-0.03%	-16.56%	-1.23%	-1.12%	-1.08%
Gross Profit Growth %	-	0.96%	-42.34%	-0.01%	-0.46%	-0.03%
Operating Expenses+	1.85M	2.12M	92.67M	43.9M	44.55M	39.39M
OpEx % of Revenue	2.48%	0.15%	82.74%	2.89%	1.83%	1.52%
Selling, General & Admin	1.85M	2.12M	18.51M	40.18M	44.55M	36.75M
SG&A % of Revenue	2.48%	0.15%	16.53%	2.64%	1.83%	1.41%
Research & Development	11.06M	15.01M	19.67M	32.66M	48.93M	51.03M
R&D % of Revenue	14.77%	1.03%	17.56%	2.15%	2.01%	1.96%
Other Operating Expenses	-11.06M	-15.01M	54.49M	-28.94M	-48.93M	-48.39M
Operating Income+	-12.17M	-2.55M	-111.22M	-62.68M	-71.93M	-67.46M
Operating Margin %	-16.25%	-0.17%	-99.3%	-4.12%	-2.95%	-2.6%
Operating Income Growth %	-	0.79%	-42.63%	0.44%	-0.15%	0.06%
EBITDA+	-12.16M	-2.54M	-111.11M	-62.52M	-71.76M	-67.27M
EBITDA Margin %	-16.24%	-0.17%	-99.21%	-4.11%	-2.95%	-2.59%
EBITDA Growth %	-	0.79%	-42.74%	0.44%	-0.15%	0.06%
D&A (Non-Cash Add-back)	5.98K	9K	105K	159K	169K	193K
EBIT	-12.17M	-2.55M	-37.06M	-58.96M	-71.93M	-64.82M
Net Interest Income+	-83.94K	-774K	-652K	2.17M	6.17M	3.77M
Interest Income	0	41K	13K	2.4M	6.4M	3.92M
Interest Expense	83.94K	815K	665K	230K	231K	154K
Other Income/Expense	-83.94K	-927K	1.13M	2.17M	6.17M	3.77M
Pretax Income+	-12.25M	-3.48M	-110.09M	-60.51M	-65.77M	-63.69M
Pretax Margin %	-16.36%	-0.24%	-98.29%	-3.98%	-2.7%	-2.45%
Income Tax+	1.3K	2K	2K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-12.26M	-3.48M	-110.09M	-60.51M	-65.77M	-63.69M
Net Margin %	-16.36%	-0.24%	-98.29%	-3.98%	-2.7%	-2.45%
Net Income Growth %	-	0.72%	-30.65%	0.45%	-0.09%	0.03%
Net Income (Continuing)	-12.26M	-3.48M	-110.09M	-60.51M	-65.77M	-63.69M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-1.65	-0.21	-12.41	-2.69	-2.44	-2.36
EPS Growth %	-	0.87%	-58.1%	0.78%	0.09%	0.03%
EPS (Basic)	-1.65	-0.21	-12.41	-2.69	-2.44	-2.36
Diluted Shares Outstanding	8.02M	17.63M	8.92M	22.51M	26.92M	27.03M
Basic Shares Outstanding	7.42M	20.84M	8.87M	22.51M	26.92M	27.03M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	16.31M	18.68M	151.27M	180.03M	124.59M	61.29M
Cash & Short-Term Investments	15.96M	4.46M	148.99M	172.56M	108.84M	47.24M
Cash Only	15.96M	4.46M	148.99M	39.02M	62.89M	28.67M
Short-Term Investments	0	0	0	133.54M	45.96M	18.57M
Accounts Receivable	284.9K	14.15M	0	1.86M	5.49M	5.9M
Days Sales Outstanding	138.83	354.21	-	44.67	82.25	82.92
Inventory	0	0	0	1.86M	6.43M	5.31M
Days Inventory Outstanding	-	-	-	19.98	45.34	35.86
Other Current Assets	0	0	0	0	3.83M	0
Total Non-Current Assets+	352.93K	140K	6.64M	4.21M	7.84M	9.03M
Property, Plant & Equipment	315.97K	140K	614K	2.03M	5.97M	7.63M
Fixed Asset Turnover	2.37x	104.14x	1.82x	7.50x	4.08x	3.40x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	3.81M	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	36.96K	0	2.21M	2.18M	1.87M	1.4M
Total Assets+	16.66M	18.82M	157.91M	184.24M	132.42M	70.32M
Asset Turnover	0.04x	0.77x	0.01x	0.08x	0.18x	0.37x
Asset Growth %	-	0.13%	7.39%	0.17%	-0.28%	-0.47%
Total Current Liabilities+	25.62M	30.06M	15.27M	18.84M	26.39M	17.07M
Accounts Payable	3.18M	2.39M	6.44M	3.52M	5.9M	2.16M
Days Payables Outstanding	104.82	58.17	119.48	37.78	41.61	14.58
Short-Term Debt	8.16M	9.03M	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	11.85M	11.61M	0	1.57M	3.08M	64K
Current Ratio	0.64x	0.62x	9.90x	9.56x	4.72x	3.59x
Quick Ratio	0.64x	0.62x	9.90x	9.46x	4.48x	3.28x
Cash Conversion Cycle	-	-	-	26.86	85.98	104.21
Total Non-Current Liabilities+	133.47K	1.2M	6.23M	7.02M	833K	767K
Long-Term Debt	0	1.1M	0	0	0	0
Capital Lease Obligations	133.47K	0	474K	1.27M	833K	565K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	97K	5.76M	5.76M	0	202K
Total Liabilities	25.75M	31.26M	21.5M	25.86M	27.23M	17.84M
Total Debt+	8.49M	10.26M	605K	1.66M	1.27M	833K
Net Debt	-7.48M	5.8M	-148.38M	-37.36M	-61.62M	-27.84M
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.02x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-144.99x	-3.13x	-167.24x	-272.53x	-311.40x	-438.04x
Total Equity+	-9.09M	-12.43M	136.41M	158.38M	105.19M	52.48M
Equity Growth %	-	-0.37%	11.97%	0.16%	-0.34%	-0.5%
Book Value per Share	-1.13	-0.71	15.29	7.04	3.91	1.94
Total Shareholders' Equity	-9.09M	-12.43M	136.41M	158.38M	105.19M	52.48M
Common Stock	802	1K	2K	2K	2K	2K
Retained Earnings	-29.12M	-32.59M	-142.69M	-203.2M	-268.96M	-332.65M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	-115K	27K	16K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.58M	-12.7M	-22.42M	-49.64M	-59.66M	-59.55M
Operating CF Margin %	-10.13%	-0.87%	-20.02%	-3.26%	-2.45%	-2.29%
Operating CF Growth %	-	-0.67%	-0.77%	-1.21%	-0.2%	0%
Net Income	-12.26M	-3.48M	-110.09M	-60.51M	-65.77M	-63.69M
Depreciation & Amortization	5.98K	9K	105K	159K	169K	193K
Stock-Based Compensation	106.14K	139K	2.11M	9.64M	11.95M	10.84M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	3.43M	2.21M	81.5M	6.11M	-2.75M	-10.61M
Working Capital Changes	1.12M	-11.59M	3.96M	-5.04M	-3.27M	3.72M
Change in Receivables	-39.7K	-13.86M	14.15M	-1.86M	-3.63M	-415K
Change in Inventory	0	0	0	-1.86M	-3.27M	1.12M
Change in Payables	0	0	0	0	0	0
Cash from Investing+	-35.71K	0	25.15M	-132.89M	83.21M	25.2M
Capital Expenditures	-35.71K	0	-46K	-444K	-3.97M	-1.65M
CapEx % of Revenue	0.05%	-	0.04%	0.03%	0.16%	0.06%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	8.07M	1.19M	141.8M	72.62M	326K	130K
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	-4.41M	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	-8.78M	120K	326K	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-7.62M	-12.7M	-22.47M	-50.08M	-63.63M	-61.2M
FCF Margin %	-10.17%	-0.87%	-20.06%	-3.29%	-2.61%	-2.36%
FCF Growth %	-	-0.67%	-0.77%	-1.23%	-0.27%	0.04%
FCF per Share	-0.95	-0.72	-2.52	-2.22	-2.36	-2.26
FCF Conversion (FCF/Net Income)	0.62x	3.65x	0.20x	0.82x	0.91x	0.93x
Interest Paid	0	0	0	230K	230K	211K
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-177.6%	-41.06%	-49.9%	-80.79%
Return on Invested Capital (ROIC)	-	-	-	-86.22%	-65.55%	-148.34%
Gross Margin	-1377.23%	-2.94%	-1656.25%	-123.43%	-112.44%	-108.04%
Net Margin	-1636.19%	-23.85%	-9829.46%	-397.69%	-270.04%	-245.13%
Debt / Equity	-	-	0.00x	0.01x	0.01x	0.02x
Interest Coverage	-144.99x	-3.13x	-167.24x	-272.53x	-311.40x	-438.04x
FCF Conversion	0.62x	3.65x	0.20x	0.82x	0.91x	0.93x
Revenue Growth	-	1846.6%	-92.32%	1258.57%	60.06%	6.69%

Frequently Asked Questions

Growth & Financials

Whitehawk Therapeutics Inc (WHWK) reported $21.6M in revenue for fiscal year 2024. This represents a 2783% increase from $0.7M in 2019.

Whitehawk Therapeutics Inc (WHWK) grew revenue by 6.7% over the past year. This is steady growth.

Whitehawk Therapeutics Inc (WHWK) reported a net loss of $10.4M for fiscal year 2024.

Dividend & Returns

Whitehawk Therapeutics Inc (WHWK) has a return on equity (ROE) of -80.8%. Negative ROE indicates the company is unprofitable.

Whitehawk Therapeutics Inc (WHWK) had negative free cash flow of $96.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener